Haematoma (number of breasts with haematoma within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy
It is very uncertain whether indocyanine Green Angiography (ICGA) changes haematoma (number of breasts with haematoma within 30 days after… compared with clinical evaluation (very low certainty).
1 finding from 1 review
RR 1.53 [0.47, 4.95]
Studies not reported
Very low
Seroma (30 days) · women undergoing immediate breast reconstruction following mastectomy
It is very uncertain whether indocyanine Green Angiography (ICGA) changes seroma (number of breast with seroma within 30 days after surgery) compared with clinical evaluation (very low certainty).
2 findings from 1 review
Reoperation · women undergoing immediate breast reconstruction following mastectomy
It is very uncertain whether indocyanine Green Angiography (ICGA) changes reoperation (number of women that were operated again within 30 days… compared with clinical evaluation (very low certainty).
2 findings from 1 review
Dehiscence · women undergoing immediate breast reconstruction following mastectomy
It is very uncertain whether indocyanine Green Angiography (ICGA) changes dehiscence (number of women with dehiscence within 30 days after… compared with clinical evaluation (very low certainty).
1 finding from 1 review
Infection (number of women with infection of the skin flap or implant within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy
It is very uncertain whether indocyanine Green Angiography (ICGA) changes infection (number of women with infection of the skin flap or… compared with clinical evaluation (very low certainty).
1 finding from 1 review
Haematoma (proportion of participants in each group with haematoma; · women undergoing immediate breast reconstruction following mastectomy
It is very uncertain whether indocyanine Green Angiography (ICGA) changes haematoma (number of women with haematoma within 30 days after… compared with clinical evaluation (very low certainty).
1 finding from 1 review
Mastectomy skin flap necrosis (number of breasts with mastectomy skin flap necrosis within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy
It is very uncertain whether indocyanine Green Angiography (ICGA) changes mastectomy skin flap necrosis (number of breasts with mastectomy… compared with clinical evaluation (very low certainty).
1 finding from 1 review
RR 0.62 [0.48, 0.82]
Studies not reported
Very low
Dehiscence ‐ not reported · women undergoing immediate breast reconstruction following mastectomy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival: Median length of · women with early breast cancer
OFS leads to lower overall survival (OS) Median compared with no OFS (high certainty).
1 finding from 1 review
Disease-free survival · women with early breast cancer
OFS leads to lower disease‐free survival (DFS) Median compared with no OFS (high certainty).
1 finding from 1 review
Toxicity ‐ hot flushes (a combination of "grade 3/4" and "any grade" toxicity) · women with early breast cancer
OFS may leads to higher toxicity ‐ hot flushes (a combination of "grade 3/4" and "any grade"… compared with no OFS (low certainty).
1 finding from 1 review
Toxicity ‐ mood · women with early breast cancer
1 finding from 1 review
Toxicity ‐ bone health (osteoporosis defined by a T score < ‐2.5) · women with early breast cancer
OFS may leads to higher toxicity ‐ bone health (osteoporosis defined by a T score < ‐2.5) compared with no OFS (low certainty).
1 finding from 1 review
Contralateral breast cancer · women with early breast cancer
OFS probably leads to lower contralateral breast cancer compared with no OFS (moderate certainty).
1 finding from 1 review
Quality of life · women with early breast cancer
1 finding from 1 review
Overall survival (OS) · women with metastatic triple‐negative breast cancer (mTNBC)
Platinum showed no clear difference in overall survival (OS) compared with non‐platinum regimens (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment discontinuation due to adverse event (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention probably leads to lower treatment discontinuation due to adverse event (safety population) (moderate certainty).
1 finding from 1 review
Time to progression · women with metastatic triple‐negative breast cancer (mTNBC)
It is very uncertain whether platinum changes progression‐free survival/time to progression (PFS/TTP) compared with non‐platinum regimens (very low certainty).
1 finding from 1 review
Tumour response · women with metastatic triple‐negative breast cancer (mTNBC)
Platinum may leads to higher objective tumour response rate (OTRR) (assessable participants) compared with non‐platinum regimens (low certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related death (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher treatment‐related death (safety population) (low certainty).
1 finding from 1 review